{
    "nct_id": "NCT04677504",
    "official_title": "A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer",
    "inclusion_criteria": "* Considered to be eligible to receive platinum-based chemotherapy, in the investigator's judgment\n* Documentation of recurrent/metastatic or locally advanced unresectable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) scans\n* Histologically or cytologically confirmed diagnosis of iCCA, eCCA, or GBC\n* No prior systemic therapy for advanced BTC\n* At least one measurable untreated lesion (per RECIST v1.1)\n* Adequate biliary drainage with no evidence of ongoing infection\n* Eastern Cooperative Oncology Group Performance Status of 0 or 1\n* Life expectancy of > 3 months\n* Adequate hematologic and end-organ function\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs\n* For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Recurrent disease <=6 months after curative surgery or <= 6 months after the completion of adjuvant therapy\n* Prior local regional therapy such as radioembolization\n* Combined or mixed hepatocellular/cholangiocarcinoma\n* Clinically significant hepatic encephalopathy within the 12 months prior to Day 1 of Cycle 1\n* National Cancer Institute Common Terminoogy Criteria for Adverse Events Grade >= 2 peripheral neuropathy\n* Prior bleeding event due to untreated or incompletely treated esophageal and/or gastric varices within 6 months prior to Day 1 of Cycle 1\n* Pregnant or breastfeeding, or intending to become pregnant during the study or within 5 months after the final dose of atezolizumab or within 6 months after the final dose of bevacizumab, cisplatin or gemcitabine\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography scan\n* History of malignancy other than BTC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death\n* Symptomatic, untreated, or actively progressing CNS metastases\n* For patients with lung metastases, if one of the following criteria applies: Large, centrally located pulmonary metastases; Clear tumor infiltration into the thoracic great vessels seen on imaging; Clear cavitation of pulmonary lesions seen on imaging\n* Active tuberculosis\n* Co-infection with HBV and HCV\n* Treatment with systemic immunostimulatory agents or immunosuppressive medication\n* Inadequately controlled arterial hypertension\n* History of hypertensive crisis or hypertensive encephalopathy\n* Significant vascular disease\n* Evidence of bleeding diathesis or significant coagulopathy\n* Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture\n* Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)\n* Preexisting renal impairment, myelosuppression, or hearing impairment",
    "miscellaneous_criteria": ""
}